Literature DB >> 23839822

Ionizing radiation enhances dl922-947-mediated cell death of anaplastic thyroid carcinoma cells.

Carmela Passaro1, Antonella Abagnale, Silvana Libertini, Massimiliano Volpe, Ginevra Botta, Laura Cella, Roberto Pacelli, Gunnel Halldèn, David Gillespie, Giuseppe Portella.   

Abstract

dl922-947 is an oncolytic adenovirus potentially suitable for the treatment of aggressive localized tumors, such as anaplastic thyroid carcinoma (ATC). In this study, we have analyzed the effects of dl922-947 in combination with ionizing radiations, testing different schedules of administration and observing synergistic effects only when ATC cells were irradiated 24 h prior to viral infection. Cells undergoing combined treatment exhibited a marked increase in cell death and viral replication, suggesting that irradiation blocks cells in a more permissive state for viral life cycle. We also show that dl922-947 triggers a DNA damage response, characterized by mobilization of the MRN complex (composed by Mre11-Rad50-Nbs1), accumulation of γH2AX, and activation of the checkpoint kinases ataxia telangiectasia mutated (ATM) and Chk1. Based on these observations, we speculate that the DNA damage response acts as a cellular protective mechanism to hinder viral infection and replication. To confirm this hypothesis, we demonstrate that the ATM inhibitor KU55933 increased the oncolytic activity of dl922-947 and its replication. Finally, we validate the potential therapeutic use of this approach by showing in vivo that the combined treatment slows tumor xenograft growth more potently than either irradiation or infection alone.

Entities:  

Keywords:  DNA damage; anaplastic thyroid carcinoma; irradiation; oncolytic virus

Mesh:

Year:  2013        PMID: 23839822     DOI: 10.1530/ERC-13-0001

Source DB:  PubMed          Journal:  Endocr Relat Cancer        ISSN: 1351-0088            Impact factor:   5.678


  9 in total

1.  PARP inhibitor olaparib increases the oncolytic activity of dl922-947 in in vitro and in vivo model of anaplastic thyroid carcinoma.

Authors:  Carmela Passaro; Massimiliano Volpe; Ginevra Botta; Eloise Scamardella; Giuseppe Perruolo; David Gillespie; Silvana Libertini; Giuseppe Portella
Journal:  Mol Oncol       Date:  2014-08-02       Impact factor: 6.603

2.  The oncolytic virus dl922-947 reduces IL-8/CXCL8 and MCP-1/CCL2 expression and impairs angiogenesis and macrophage infiltration in anaplastic thyroid carcinoma.

Authors:  Carmela Passaro; Francesco Borriello; Viviana Vastolo; Sarah Di Somma; Eloise Scamardella; Vincenzo Gigantino; Renato Franco; Gianni Marone; Giuseppe Portella
Journal:  Oncotarget       Date:  2016-01-12

3.  Bioinformatics analysis of key genes and latent pathway interactions based on the anaplastic thyroid carcinoma gene expression profile.

Authors:  Yun Huang; Yiming Tao; Xinying Li; Shi Chang; Bo Jiang; Feng Li; Zhi-Ming Wang
Journal:  Oncol Lett       Date:  2016-11-30       Impact factor: 2.967

4.  Recombinant oncolytic Newcastle disease virus displays antitumor activities in anaplastic thyroid cancer cells.

Authors:  Ke Jiang; Cuiping Song; Lingkai Kong; Lulu Hu; Guibin Lin; Tian Ye; Gang Yao; Yupeng Wang; Haibo Chen; Wei Cheng; Martin P Barr; Quentin Liu; Guirong Zhang; Chan Ding; Songshu Meng
Journal:  BMC Cancer       Date:  2018-07-18       Impact factor: 4.430

Review 5.  Virotherapy as a Potential Therapeutic Approach for the Treatment of Aggressive Thyroid Cancer.

Authors:  Anna Maria Malfitano; Sarah Di Somma; Nella Prevete; Giuseppe Portella
Journal:  Cancers (Basel)       Date:  2019-10-10       Impact factor: 6.639

6.  Combination of dl922-947 Oncolytic Adenovirus and G-Quadruplex Binders Uncovers Improved Antitumor Activity in Breast Cancer.

Authors:  Fabiana Napolitano; Sarah Di Somma; Giuliano Castellano; Jussara Amato; Bruno Pagano; Antonio Randazzo; Giuseppe Portella; Anna Maria Malfitano
Journal:  Cells       Date:  2022-08-10       Impact factor: 7.666

Review 7.  Therapeutic advances in anaplastic thyroid cancer: a current perspective.

Authors:  Shikha Saini; Kiara Tulla; Ajay V Maker; Kenneth D Burman; Bellur S Prabhakar
Journal:  Mol Cancer       Date:  2018-10-23       Impact factor: 27.401

8.  Combination Therapy with Reovirus and ATM Inhibitor Enhances Cell Death and Virus Replication in Canine Melanoma.

Authors:  Masaya Igase; Shusaku Shibutani; Yosuke Kurogouchi; Noriyuki Fujiki; Chung Chew Hwang; Matt Coffey; Shunsuke Noguchi; Yuki Nemoto; Takuya Mizuno
Journal:  Mol Ther Oncolytics       Date:  2019-08-28       Impact factor: 7.200

9.  Pharmacological Inhibition of WEE1 Potentiates the Antitumoral Effect of the dl922-947 Oncolytic Virus in Malignant Mesothelioma Cell Lines.

Authors:  Carmelina Antonella Iannuzzi; Paola Indovina; Iris Maria Forte; Sarah Di Somma; Anna Maria Malfitano; Martina Bruno; Giuseppe Portella; Francesca Pentimalli; Antonio Giordano
Journal:  Int J Mol Sci       Date:  2020-10-04       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.